Purchase Order 75N95023P00689
Award Date 9/1/23
Potential Completion Date 8/31/24
Potential Value $16K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Reaction Biology Corporation has been awarded a $100,560 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to provide GAMMA 33P ATP Kinase Assay and NanoBRET Kinase Assay testing services. As a prime contractor, Reaction Biology will utilize its Kinase HotSpot and Methyltransferase HotSpot platforms to test libraries of novel compounds against panels of wild-type kinases and...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...
- This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
- This $34,884 fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a small disadvantaged business, to conduct kinase inhibition testing on 100 novel small molecule compounds. The contract supports the work of the National Center for Advancing Translational Sciences (NCATS) within NIH, which is focused on developing potential anti-cancer agents. Reaction Biology will use its...
- This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...
- This $19,833.68 firm fixed-price purchase order contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for profiling 10 BTK (Bruton's tyrosine kinase) inhibitors against a panel of 20 kinases. Reaction Biology is a drug discovery contract research organization that specializes in enzyme...
- This $29,376 firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The award is to obtain kinase hotspot assay compound testing services from Reaction Biology. This contract is not associated with a larger vehicle. The purpose is to test 120 novel small molecule compounds for inhibitory activity...